New Insights on Disintegrin-Receptor Interactions: Eristostatin and Melanoma Cells

Viper venom disintegrins have been used frequently to study the cellular receptors which characterize various types of cells, including platelets, endothelial cells and cancer cells. While the majority of such analyses have pointed to involvement of integrin receptors αvβ3, α5β1 or αIIbβ3, this may not always be so. Eristostatin, from Eristocophis macmahoni, is a potent inhibitor of ADP-induced platelet aggregation as well as of human and murine melanoma metastases in mouse model systems. This disintegrin requires an RGDW motif, as well as an intact C-terminus, in order to interact with both platelets and four different types of melanoma cells. Eristostatin causes nonmetastatic SBc12 melanoma cells to show higher susceptibility to specific killing by NK-like TALL-104 cells. While it is known that eristostatin binds to αIIbβ3 on platelets, the receptor with which eristostatin binds to the melanoma cells has not yet been identified.

[1]  A. Epstein,et al.  Molecular cloning and functional expression of contortrostatin, a homodimeric disintegrin from southern copperhead snake venom. , 2000, Archives of biochemistry and biophysics.

[2]  P. Brooks,et al.  Contortrostatin, a Homodimeric Disintegrin, Binds to Integrin αvβ5 , 2000 .

[3]  M. Colonna,et al.  2B4: an NK cell activating receptor with unique specificity and signal transduction mechanism. , 2000, Human immunology.

[4]  J. Calvete,et al.  Structural Requirements of Echistatin for the Recognition of αvβ3 and α5β1Integrins* , 1999, The Journal of Biological Chemistry.

[5]  R. Zingali,et al.  Effects of jarastatin, a novel snake venom disintegrin, on neutrophil migration and actin cytoskeleton dynamics. , 1999, Experimental cell research.

[6]  D. S. Kim,et al.  A novel disintegrin salmosin inhibits tumor angiogenesis. , 1999, Cancer research.

[7]  M. Raida,et al.  EC3, a Novel Heterodimeric Disintegrin from Echis carinatus Venom, Inhibits α4 and α5 Integrins in an RGD-independent Manner* , 1999, The Journal of Biological Chemistry.

[8]  J. Calvete,et al.  Structural requirements of echistatin for the recognition of alpha(v)beta(3) and alpha(5)beta(1) integrins. , 1999, The Journal of biological chemistry.

[9]  M. Raida,et al.  EC3, a novel heterodimeric disintegrin from Echis carinatus venom, inhibits alpha4 and alpha5 integrins in an RGD-independent manner. , 1999, The Journal of biological chemistry.

[10]  S. Vijay-Kumar,et al.  Viper Venom Disintegrins and Related Molecules , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[11]  E. Danen,et al.  The Disintegrin Eristostatin Interferes with Integrin α4β1 Function and with Experimental Metastasis of Human Melanoma Cells , 1998 .

[12]  E. Danen,et al.  The disintegrin eristostatin interferes with integrin alpha 4 beta 1 function and with experimental metastasis of human melanoma cells. , 1998, Experimental cell research.

[13]  C. Abrass,et al.  Heparin binding domain of insulin-like growth factor binding protein-5 stimulates mesangial cell migration. , 1997, American journal of physiology. Renal physiology.

[14]  Yuqin Wang,et al.  Disintegrin Interaction with αvβ3Integrin on Human Umbilical Vein Endothelial Cells: Expression of Ligand-Induced Binding Site on β3Subunit , 1996 .

[15]  L. A. Rosenthal,et al.  Disintegrin interaction with alpha V beta 3 integrin on human umbilical vein endothelial cells: expression of ligand-induced binding site on beta 3 subunit. , 1996, Experimental cell research.

[16]  R. Khokha,et al.  Effects of the disintegrin eristostatin on individual steps of hematogenous metastasis. , 1995, Experimental cell research.

[17]  S. Niewiarowski,et al.  Effect of four disintegrins on the adhesive and metastatic properties of B16F10 melanoma cells in a murine model. , 1995, Oncology research.

[18]  M. Kowalska,et al.  Interaction of disintegrins with the alpha IIb beta 3 receptor on resting and activated human platelets. , 1994, The Biochemical journal.

[19]  V. Fried,et al.  Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. , 1991, The Journal of biological chemistry.

[20]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[21]  E. Ruoslahti,et al.  [27] Arginine-glycine-aspartic acid adhesion receptors , 1987 .

[22]  E. Ruoslahti,et al.  Arginine-glycine-aspartic acid adhesion receptors. , 1987, Methods in enzymology.

[23]  E. Ruoslahti,et al.  Arginyl-glycyl-aspartic acid sequences and fibrinogen binding to platelets. , 1987, Blood.